Fennec Pharmaceuticals In... (FENC)
NASDAQ: FENC
· Real-Time Price · USD
6.34
0.23 (3.76%)
At close: May 02, 2025, 3:59 PM
6.30
-0.71%
After-hours: May 02, 2025, 04:05 PM EDT
Company Description
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company.
Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients.
The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014.
Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Fennec Pharmaceuticals Inc.
| Country | United States |
| IPO Date | Sep 15, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 32 |
| CEO | Christiana Cioffi M.B.A. |
Contact Details
Address: 68 TW Alexander Drive Research Triangle Park, North Carolina United States | |
| Website | https://www.fennecpharma.com |
Stock Details
| Ticker Symbol | FENC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001211583 |
| CUSIP Number | 31447P100 |
| ISIN Number | CA31447P1009 |
| Employer ID | 00-0000000 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Christiana Cioffi M.B.A. | Chief Strategy Officer |
| Lei Fang | President of Pharstat Inc |
| Mark Gowland | Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 01, 2025 | 4 | Filing |
| May 01, 2025 | 4 | Filing |
| Apr 25, 2025 | DEF 14A | Filing |
| Apr 04, 2025 | 4 | Filing |
| Apr 03, 2025 | 4/A | [Amend] Filing |
| Apr 03, 2025 | 4 | Filing |
| Apr 03, 2025 | 4/A | [Amend] Filing |
| Apr 03, 2025 | 4/A | [Amend] Filing |
| Apr 03, 2025 | 4 | Filing |
| Apr 03, 2025 | 4 | Filing |